Townsquare Capital LLC Increases Stock Holdings in GSK plc (NYSE:GSK)

Townsquare Capital LLC raised its position in GSK plc (NYSE:GSK) by 7.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,367 shares of the pharmaceutical company’s stock after acquiring an additional 7,151 shares during the quarter. Townsquare Capital LLC’s holdings in GSK were worth $4,021,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of GSK. Transamerica Financial Advisors Inc. grew its holdings in shares of GSK by 1,488.2% in the third quarter. Transamerica Financial Advisors Inc. now owns 3,494 shares of the pharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,274 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of GSK by 692.3% in the third quarter. Quantbot Technologies LP now owns 210,810 shares of the pharmaceutical company’s stock worth $8,618,000 after acquiring an additional 184,204 shares in the last quarter. FMR LLC increased its position in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of GSK by 0.8% in the third quarter. The Manufacturers Life Insurance Company now owns 1,018,489 shares of the pharmaceutical company’s stock valued at $41,636,000 after acquiring an additional 7,990 shares in the last quarter. Finally, Horizon Kinetics Asset Management LLC boosted its holdings in GSK by 51.8% in the third quarter. Horizon Kinetics Asset Management LLC now owns 38,192 shares of the pharmaceutical company’s stock valued at $1,561,000 after purchasing an additional 13,027 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on GSK. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Argus upgraded shares of GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Barclays upgraded shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Seven equities research analysts have rated the stock with a hold rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Down 0.6 %

Shares of GSK stock opened at $34.13 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The company has a fifty day simple moving average of $37.29 and a 200-day simple moving average of $40.01. The stock has a market cap of $70.74 billion, a price-to-earnings ratio of 22.16, a PEG ratio of 1.31 and a beta of 0.66. GSK plc has a 12-month low of $32.83 and a 12-month high of $45.92.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a $0.3928 dividend. This represents a $1.57 annualized dividend and a yield of 4.60%. The ex-dividend date is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is currently 99.35%.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction dated Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.